Clario’s Latest Innovation in Cardiac Safety Assessment
Clario, a prominent healthcare research technology company renowned for its cutting-edge endpoint technology solutions in clinical trials, has unveiled its innovative AI-powered ECG Quality Score tool. This tool, which marks a significant advancement in Clario’s quest for enhanced accuracy and efficiency in cardiac safety assessments, utilizes a distinctive artificial intelligence and machine learning methodology to bolster the quality of cardiac safety data.
The primary objective of the AI-powered ECG Quality Score tool is to furnish sponsors with actionable insights, empowering them to take proactive measures and instilling confidence in the data quality. By complementing Clario’s leading Early Precision QT® (EPQT) solution, this tool has the potential to facilitate waivers of traditional Thorough QT (TQT) studies, thereby streamlining the clinical trial process.
Ellen Street, the Executive Vice President of Cardiac Safety at Clario, expressed her excitement about this groundbreaking development, emphasizing Clario’s steadfast commitment to leveraging AI/ML technologies to revolutionize trials and enhance decision-making processes for sponsors.
This innovative tool, which has been meticulously trained on a vast database of over 80,000 Phase 1 Healthy Volunteer ECGs, delivers detailed assessments on the quality of continuous ECG data, ensuring its suitability for further EPQT analysis. By offering a proactive approach to monitoring study quality in real-time, Clario can promptly address any issues that may arise, such as providing additional training to sites or implementing recruitment strategies, thereby serving as a safeguard for ongoing and prospective studies.
The ECG Quality Score tool comprises two comprehensive reports – the Early Precision QT® Quality Summary Report and the Early Precision QT® Quality Detailed Report – which collectively offer in-depth insights into the quality of the collected ECG data. Through these reports, sponsors gain valuable information that enhances data quality assurance, mitigates risks, and enhances the likelihood of achieving conclusive trial results.
As part of its commitment to innovation and partnership, Clario will initially introduce the ECG Quality Score tool to its Certified Sites, underscoring its dedication to providing cutting-edge technology to its closest collaborators first.
In conclusion, Clario’s AI-powered ECG Quality Score tool represents a pivotal advancement in cardiac safety assessment, exemplifying the company’s dedication to driving progress in clinical trials through the integration of advanced technologies and data-driven insights.
